Insider · CIK 0001895357
George Kottayil
Files at GRCE (Acasti Pharma Inc.). First filing -, latest -.
In brief
George Kottayil files SEC Form 4 as director at GRCE (Acasti Pharma Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; George Kottayil has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +12,200 | $0.00 | $0 | 12,200 | 22 d ago |
| Jan 8, 2026 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| May 9, 2025 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| Dec 19, 2023 | GRCE Acasti Pharma Inc. | AGrant or award Stock Options (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Dec 20, 2023 |
Questions about George Kottayil
Answered from the filings on this page, as of the latest one.
Is George Kottayil buying or selling?
George Kottayil has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did George Kottayil's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and George Kottayil has 0.
Where does George Kottayil file Form 4?
George Kottayil has filed Form 4 at GRCE (Acasti Pharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.